Summary
The expression of p53 protein was examined in a series of 111 colorectal cancer adenocarcinomas with a long follow-up. A quantitative luminometric immunoassay (LIA) was used for the measurement of wild-type and mutant p53 protein in extracts from colorectal tumour cytosols, p53 being detected in 42% of the samples (range 0.0–52 ng mg–1). Using an arbitrary cut-off value of 2.7 ng mg–1, 25% of the tumours were classified as manifesting high p53 levels. There was no association of p53 expression with patient age, sex, serum preoperative carcinoembryonic antigen (CEA) levels, tumour site and size, nodal status or TNM stage. Significant and independent correlation was found to exist between high p53 levels and prolonged disease-free survival (P = 0.05) at a median follow-up of 60 months. This survival advantage was most apparent among stage III cancer patients. The results from this study would suggest that expression of high p53 levels appear to be useful in selecting a group of colorectal cancer patients with a better prognosis.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ahnen, DJ, Feigl, P, Quan, G, Fenoglio-Preiser, C, Lovato, L, Bunn, PA Jr, Stemmerman, G, Wells, JD, MacDonald, JJ & Meyskens, FL Jr (1998). Ki-ras mutation and p53 overexpression predict the clinical behaviour of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58: 1149–1158.
Auvinen, A, Isola, J, Visakorpi, T, Koivula, T, Virtanen, S & Hakama, M (1994). Overexpression of p53 and long term survival in colon carcinoma. Br J Cancer 70: 293–296.
Børresen-Dale, AL, Lothe, RA, Meling, GI, Hainault, P, Torlaiv, OR & Skovlund, E (1998). TP53 and long-term prognosis in colorectal cancer, mutations in the L3 Zn-binding domain predict poor survival. Clin Cancer Res 1: 203–210.
Battifora, H (1994). p53 immunochemistry: a word of caution. Hum Pathol 25: 435–436.
Bell, S, Scott, N, Cross, D, Sagar, P, Lewis, FA, Blaire, GE, Taylor, GR, Dixon, MF & Quirke, P (1993). Prognostic value of p53 overexpression and c-ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57–64.
Borg, A, Lennerstand, J, Stenmark-Askmalm, M, Ferno, M, Bristors, A, Ohrvik, A, Stal, O, Killander, D, Lane, D & Brundell, J (1995). Prognostic significance of p53 overexpression in primary breast cancer: a novel luminometric immunoassay applicable on steroid receptors cytosols. Br J Cancer 71: 1013–1017.
Campbell, C, Quinn, AG, Angus, B, Farr, PM & Rees, JL (1993). Wavelength-specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res 53: 2697–2699.
Cho, Y, Gorina, S, Jeffrey, PD & Pavletich, NP (1994). Crystal structure of a p53 tumour suppresser DNA complex: understanding tumorigenic mutations. Science 265: 346–355.
Dix, B, Robbins, P, Carello, A, House, A & Iacopetta, B (1994a). Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 70: 585–590.
Dix, BR, Robbins, P, Soong, R, Jenner, D, Hove, AK & Iacopetta, BI (1994b). The common molecular genetic alterations in Dukes’ B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 50: 747–751.
Eid, H, Van der Looij, M, Institoris, E, Géczi, L, Bodrogi, I, Olah, E & Bak, M (1997). Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer?. Anticancer Res 17: 2663–2670.
Elledge, RM & Allred, DC (1994). The p53 tumour suppressor gene in breast cancer. Breast Cancer Res Treat 32: 39–47.
Kastan, MB, Onyekwere, O, Sidransky, D, Vogelstein, B & Craig, RW (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304–6311.
Kressner, U, Lindmark, G, Gerdin, B, Pahlman, L & Glimelius, B (1996). Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 16: 951–958.
Lee, JS, Yoon, A, Kalapurakal, SK, Ro, J, Lee, J, Tu, N, Hittleman, WN & Hong, WK (1995). Expression of p53 oncoprotein in non-small cell lung cancer: a favourable prognostic factor. J Clin Oncol 13: 1893–1903.
Levine, AJ, Perry, ME, Chang, A, Silver, A, Dittmer, D, Wu, M & Welsh, D (1994). The 1993 Walter Hubert Lecture: the role of p53 tumour suppresser gene in tumoriginesis. Br J Cancer 69: 409–416.
Mulder, JWR, Baas, IO, Polak, MM, Goodman, SN & Offerhans, GJA (1995). Evaluation of p53 protein expression as a marker for long term prognosis in colorectal carcinoma. Br J Cancer 71: 1257–1262.
Nathanson, SD, Linden, MD, Tender, P, Zarbo, RJ, Jacobsen, G & Nelson, LT (1994). Relationship among p53, stage and prognosis of large bowel cancer. Dis Colon Rectum 37: 527–534.
Ofner, D, Maier, H, Riedmann, B, Holzberger, P, Nogler, M, Totsch, M, Bankfalvi, A, Winde, G, Bócker, W & Schmid, KW (1995). Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J Clin Pathol Mol Pathol 48: 12–16.
Poller, DN, Baxter, KJ & Sepherd, NA (1997). P53 and Rb1 protein expression: are they any prognostically useful in colorectal cancer?. Br J Cancer 75: 87–93.
Scott, N, Sagar, P, Stewart, J, Blair, G, Dixon, M & Quirke, P (1991). P53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63: 317–319.
Sjögren, S, Inganäs, M, Norberg, T, Lindgren, A, Nordgren, H, Holmberg, L & Bergh, J (1996). The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173–182.
Soong, R, Grieu, F, Robbins, P, Dix, B, Chen, D, Parsons, R, House, A & Iacopetta, B (1997). P53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3: 1405–1411.
Starzynska, T, Bromley, M, Ghosh, A & Stern, PL (1992). Prognostic significance of p53 overexpression in gastric and colorectal carcinomas. Br J Cancer 66: 558–562.
Sun, XF, Carstenten, JM, Stal, O, Zhang, H, Nilsson, E, Sjödahl, R & Nordenskjöld, B (1993). Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virch Arch A Pathol Anat 423: 443–448.
Tominaga, O, Hamelin, R, Remvikos, Y, Salmon, RJ & Thomas, G (1992). p53 from basic research to clinical applications. Crit Rev Oncog 3: 257–282.
Viale, G (1997). Prognostic and predictive value of p53 aberrations in tumours of the gastrointestinal tract and pancreas. In: Prognostic and Predictive Value of p53, Vol. 1, Klijn JGM (ed), pp. 131–141. ESO Scientific Updates, Elsevier: Amsterdam
Wynford-Thomas, D (1994). P53 in tumour pathology: can we trust immunocytochemistry?. J Pathol 166: 329–330.
Yamaguchi, A, Kurosaka, Y, Fushida, S, Kanno, M, Yonemura, Y, Miwa, K & Miyazaki, I (1992). Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70: 2778–2784.
Yamaguchi, A, Nakagawa, G, Kurosaka, Y, Nishimura, G, Yonemura, Y & Miyazakii, T (1993). P53 immunoreaction in endoscopic biopsy specimens of colorectal cancer and its prognostic significance. Br J Cancer 68: 399–402.
Zeng, ZS, Sarkis, AS, Zhang, ZF, Klimstra, DS, Charytonowicz, E, Guillén, JG, Cordón-Cardo, C & Cohen, AM (1994). P53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12: 2043–2050.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Adrover, E., Maestro, M., Sanz-Casla, M. et al. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. Br J Cancer 81, 122–126 (1999). https://doi.org/10.1038/sj.bjc.6690660
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690660
Keywords
This article is cited by
-
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer
Modern Pathology (2020)
-
Prognostic value of p53 for colorectal cancer after surgical resection of pulmonary metastases
World Journal of Surgical Oncology (2016)
-
Blastocystis sp. subtype 3 triggers higher proliferation of human colorectal cancer cells, HCT116
Parasitology Research (2013)
-
Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?
Clinical and Translational Oncology (2012)
-
Molecular markers to individualize adjuvant therapy for colon cancer
Nature Reviews Clinical Oncology (2010)